Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia;Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos

Revista de Psiquiatria y Salud Mental

Volumn 9, Issue 3, 2016, Pages 158-173

  Montejo, Ángel L ^a   Arango, Celso ^b   Bernardo, Miguel ^c   Carrasco, José L ^d   Crespo Facorro, Benedicto ^e   Cruz, Juan J ^a   del Pino, Javier ^a   García Escudero, Miguel A ^f   García Rizo, Clemente ^c   González Pinto, Ana ^g   Hernández, Ana I ^h   Martín Carrasco, Manuel ^i,j   Mayoral Cleries, Fermin ^k   Mayoral van Son, Jaqueline ^l   Mories, M Teresa ^a   Pachiarotti, Isabella ^c   Ros, Salvador ^m   Vieta, Eduard ^c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e UNIVERSITY OF CANTABRIA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^g UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^h Red de Salud Mental de Guipúzcoa   (Spain)

ⁱ Instituto de Investigaciones Psiquiatricas   (Spain)

^j CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^k HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^l HOSPITAL SIERRALLANA   (Spain)

^m Instituto Internacional de Neurociencias Aplicadas   (Spain)

more..

Author keywords

Antipsychotic drugs; Consensus; Iatrogenic hyperprolactinaemia; Schizophrenia; Sexual dysfunction

Indexed keywords

ESTROGEN; NEUROLEPTIC AGENT; PROLACTIN; SEX HORMONE; VITAMIN D;

AMENORRHEA; BONE MASS; CANCER RISK; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DRUG SAFETY; ENDOCRINOLOGY; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; IMMUNOPATHOLOGY; INTERNAL MEDICINE; MENOPAUSE; ONCOLOGY; PSYCHIATRY; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SHORT SURVEY; SYMPTOM; CHEMICALLY INDUCED; COMPLICATION; CONSENSUS DEVELOPMENT; PATHOPHYSIOLOGY; RISK FACTOR; SPAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; HYPERPROLACTINEMIA; RISK ASSESSMENT; RISK FACTORS; SPAIN;

EID: 84959122898     PISSN: 18889891     EISSN: 19894600     Source Type: Journal    
DOI: 10.1016/j.rpsm.2015.11.003     Document Type: Short Survey

References (178)

1. 1 Fagiolini, A., Montejo, A.L., Thomas, P., Millar, H., Physical health considerations in psychiatry: Views on recognition, monitoring and management. Eur Neuropsychopharmacol, 18(Suppl 2), 2008, S10.
2. 2 Sáiz Ruiz, J.J., Bobes García, J., Vallejo Ruiloba, J., Giner Ubago, M.P., García-Portilla González, J., Grupo de Trabajo sobre la Salud Física del Paciente con Esquizofrenia. [Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry] [artículo en español]. Actas Esp Psiquiatr 36 (2008), 251–264.
3. 3 Montejo, A.L., Prolactin awareness: An essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 18:supl 2 (2008), 101–130.
4. 4 Montejo, A.L., Rico Villademoros, F., Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRsexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther 34 (2008), 227–239.
5. 5 Byerly, M., Suppes, T., Tran, Q.V., Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 27 (2007), 639–661.
6. 6 Arango, C., Bobes, J., Aranda, P., Carmena, R., Garcia-Garcia, M., Rejas, J., Clamors Study Collaborative Group. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr Res. 104:1-3 (2008), 1–12.
7. 7 Bushe, C., Shaw, M., Peveler, R., A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 22 (2008), 46–55.
8. 8 Volavka, J., Czobor, P., Cooper, T.B., Sheitman, B., Lindenmayer, J.P., Citrome, L., et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 65 (2004), 57–61.
9. 9 Inder, W.J., Castle, D., Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 45 (2011), 830–837.
10. 10 Cookson, J., Hodgson, R., Hiram, J.W., Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis. J Psychopharmacol 26 (2012), 42–51.
11. 11 Laita, P., Cifuentes, A., Doll, A., Llorente, C., Cortés, I., Parellada, M., et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 17 (2007), 487–502.
12. 12 Aichhorn, W., Whitworth, A.B., Weiss, E.M., Hinterhuber, H., Marksteiner, J., [Differences between men and women in side effects of second-generation antipsychotics] [artículo en alemán]. Der Nervenarzt 78 (2007), 45–52.
13. 13 Pérez-Iglesias, R., Mata, I., Martínez-García, O., Garcia-Unzueta, M.T., Amado, J.A., Valdizán, E.M., et al. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. J Clin Psychopharmacol. 32 (2012), 804–808.
14. 14 Roussidis, A., Kalkavoura, C., Dimelis, D., Reasons and clinical outcomes of antypsicotic treatment switch in outpatients with schizophrenia in real-life clinical settings: The ETOS observational study. Ann Gen Psychiatry, 12, 2013, 42.
15. 15 DiBonaventura, M., Gabriel, S., Dupclay, A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry, 12, 2012, 20.
16. 16 Basson, R., Rees, P., Wang, R.X., Montejo, A.L., Incrocci, L., Sexual function in chronic illness. J Sex Med 7:1 Pt 2 (2010), 374–388.
17. 17 Montejo, A.L., Majadas, S., Rico-Villademoros, F., Llorca, G., de la Gándara, J., Franco, M., et al., for the Spanish Working Group for the Study of Psychotropic-Related Sexual. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. J Sex Med. 7 (2010), 3404–3413.
18. 18 Rickenlund, A., Thoren, M., Carlstrom, K., von Schoultz, B., Hirschberg, A.L., Diurnal profiles of testosterone and pituitary hormones suggest different mechanisms for menstrual disturbances in endurance athletes. J Clin Endocrinol Metab. 89 (2004), 702–707.
19. 19 Freeman, M.E., Kanyicska, B., Lerant, A., Nagy, G., Prolactin: Structure, function and regulation of secretion. Physiol Rev. 80 (2000), 1523–1631.
20. 20 Frantz, A.G., Prolactin. N Engl J Med 298 (1978), 201–207.
21. 21 Melmed, S., Casanueva, F.F., Hoffman, R.A., Kleinberg, L.D., Montori, M.V., Schlechte, A.J., et al., Endocrine Society. Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 96 (2011), 273–288.
22. 22 Ignacak, A., Kasztelnik, M., Sliwa, T., Korbut, R., Rajda, K., Guzik, T., Prolactin not only lactotrophin. A «new» view of the «old» hormone. J Physiol Pharmacol. 63 (2012), 435–443.
23. 23 Benker, G., Jaspers, C., Hausler, G., Reinwein, D., Control of prolactin secretion. Klin Wochenschr. 68 (1990), 1157–1167.
24. 24 Holt, R.I., Hanley, N.A., Summary of the regulation and effects of prolactin. In Chapter 5, The hypothalamus and pituitary gland. 2006, Blackwell Publishing, Essential Endocrinology, 66.
25. 25 McCann, S.M., Lumpkin, M.D., Mizunuma, H., Khorram, O., Samson, W., Recent studies on the role of brain peptides in control of anterior pituitary hormone secretion. Peptides. 5:Suppl (1984), 3–7.
26. 26 Tuomisto, J., Mannisto, P., Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev. 37 (1985), 249–332.
27. a ed., 2009, Elsevier, Madrid, 159–267.
28. 28 Gudelsky, G.A., Tuberoinfundibular dopamine neurons and regulation of ptolactin secretion. Psychoneuroendocrinology. 6 (1981), 3–16.
29. 29 Formicheva, E., Nemirovich-Danchenko, E., Korneva, E., Immunoprotective effects of prolactin during stress induced immune dysfunction. Bull Exp Biol Med. 137 (2004), 544–547.
30. 30 De Bellis, A., Bizzarro, A., Pivonello, R., Lombardi, G., Bellastella, A., Prolactin and autoimmunity. Pituitary 8 (2005), 25–30.
31. 31 Dorshkind, K., Horseman, N., The roles of prolactin, growth hormone, insulin-like growth factor-i, and thyroid hormones in lymphocyte development and function: Insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 21 (2000), 292–312.
32. 32 Serri, O., Chik, C.L., Ur, E., Diagnosis and management of hyper-prolactinemia. CMAJ 169 (2003), 575–581.
33. 33 Colao, A., Sarno, A.D., Cappabianca, P., Briganti, F., Pivonello, R., Somma, C.D., et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 148 (2003), 325–331.
34. 34 Kinon, B.J., Gilmore, J.A., Liu, H., Halbreich, U.M., Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinol 28:Suppl 2 (2003), 55–68.
35. 35 Chwieduk, C.M., Keating, G.M., Paliperidone extended release: A review of its use in the management of schizophrenia. Drugs 70 (2010), 1295–1317.
36. 36 Bellantuono, C., Santone, G., [Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder] [artículo en italiano]. Riv Psichiatr 47 (2012), 5–20.
37. 37 Janicak, P.G., Winans, E.A., Paliperidone ER: A review of the clinical trial data. Neuropsychiatr Dis Treat 3 (2007), 869–897.
38. 38 Besnard, I., Auclair, V., Callery, G., Gabriel-Bordenave, C., Roberge, C., [Antipsychotic-drug-induced hyperprolactinemia: Physiopathology, clinical features and guidance] [artículo en francés]. Encephale. 40 (2014), 86–94.
39. 39 Arakawa, R., Okumura, M., Ito, H., Takano, A., Takahashi, H., Takano, H., et al. Positron emission tomography measurement of dopamine D receptor occupancy in the pituitary and cerebral cortex: Relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 71 (2010), 1131–1137.
40. 40 Paparrigopoulos, T., Liappas, J., Tzavellas, E., Mourikis, I., Soldatos, C., Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007), 92–96.
41. 41 Bushe, C.J., Bradley, A., Pendlebury, J., A review of hyperprolactinaemia and severe mental illness: Are there implications for clinical biochemistry?. Ann Clin Biochem. 47 (2010), 292–300.
42. 42 Juruena, M.F., Pondé de Sena, E., Reis de Oliveira, I., Safety and tolerability of antipsychotics: Focus on amisulpride. Drug Healthc Patient Saf 2 (2010), 205–211.
43. 43 Bargiota, S.I., Bonotis, K.S., Messinis, I.E., Angelopoulos, N.V., The effects of antipsychotics on prolactin levels and women's menstruation. Schizophr Res Treatment, 2013, 502697.
44. 44 Rao, V.A., Bishop, M., Coppen, A., Clinical state, plasma levels of haloperidol and prolactin: A correlation study in chronic schizophrenia. Br J Psychiatry 137 (1980), 518–521.
45. 45 Wiles, D., Franklin, M., Dencker, S.J., Johansson, R., Lundin, L., Malm, U., Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. Psychopharmacology 71 (1980), 131–136.
46. 46 Smith, S., The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol 22 (2008), 63–69.
47. 47 Svestka, J., Synek, O., Tomanová, J., Differences in the effect of second-generation antipsychotics on prolactinaemia: 6 weeks open-label trial in female in-patients. Neuro Endocrinol Lett 28 (2007), 881–888.
48. 48 Cruz, N., Vieta, E., Asenapine: A new focus on the treatment of mania. Rev Psiquiatr Salud Ment. 4 (2011), 101–108.
49. 49 Montejo, A.L., Rico-Villademoros, F., Daniel, E., Derecho, J., Franch, J., Franco, M., et al. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: A 3-month, prospective, observational study. J Clin Psychopharmacol 28 (2008), 568–570.
50. 50 Crawford, A.M., Beasley, C.M. Jr., Tollefson, G.D., The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 26 (1997), 41–54.
51. 51 Peuskens, J., Pani, L., Detraux, J., De Hert, M., The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs 28 (2014), 421–453.
52. 52 Leucht, S., Cipriani, A., Spineli, L., Comparative efficacy and tolerability of 15 antipsychoticdrugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 382 (2013), 951–962.
53. 53 Aston, J., Rechsteiner, E., Bull, N., Borgwardt, S., Gschwandtner, U., Riecher-Rössler, A., Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 34 (2010), 1342–1344.
54. 54 Garcia-Rizo, C., Fernandez-Egea, E., Oliveira, C., Justicia, A., Parellada, E., Bernardo, M., et al. Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res. 134 (2012), 16–19.
55. 55 Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P., et al., EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet. 371 (2008), 1085–1097.
56. 56 Shrivastava, A., Johnston, M., Bureau, Y., Shah, N., Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at 5 years: Is it a predictive factor?. Innov Clin Neurosci. 9 (2012), 17–21.
57. 57 Riecher-Rössler, A.L., Rybakowski, J.K., Pflueger, M.O., Beyrau, R., Kahn, R.S., Malik, P., et al., EUFEST Study Group. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol Med 43 (2013), 2571–2582.
58. 58 Segal, M., Avital, A., Rojas, M., Hausvater, N., Sandbank, S., Liba, D., et al. Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: A possible marker for the disease's subtypes. Psychiatry Res. 127 (2004), 227–235.
59. 59 Hernandez A.I., Montejo AL, Prieto N, Sánchez S, Gallego MT, Bote B, et al. EPA: 1694 Antipsychotics and prolactin. Study of prevalence and associated sexual dysfunction. Eur Psychiatr. 2014;29(Supp 1):1. Disponible en: http://dx.doi.org/10.1016/S0924-9338(14)78837-6.
60. 60 Rettenbacher, M.A., Hofer, A., Ebenbichler, C., Baumgartner, S., Edlinger, M., Engl, J., et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J Clin Psychopharmacol. 30 (2010), 711–715.
61. 61 Howard, L., Kirkwood, G., Leese, M., Risk of hip fracture in patients with a history ofschizophrenia. Br J Psychiatry. 190 (2007), 129–134.
62. 62 McNeilly, A.S., Neuroendocrine changes and fertility in breastfeeding women. Prog Brain Res. 133 (2001), 207–214.
63. 63 Casanueva, F.F., Molicth, M.E., Schlechthe, J., Abs, R., Bonert, V., Bronstein, M., et al. Guidelines of de pituitray society for the diagnosis and management of prolactinoma. Clin Endocrinol 65 (2006), 265–273.
64. 64 Mancini, T., Casanueva, F.F., Giustina, A., Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37 (2008), 67–99 viii.
65. 65 Bolyakov, A., Paduch, D.A., Prolactin in men's health and disease. Curr Opin Urol. 21 (2011), 527–534.
66. 66 Solis, J., Cornejo, P., Estados hiperprolactinémicos. Red Med Hered. 17 (2006), 234–245.
67. 67 Fideleff, H.L., Boquete, H.R., Suárez, M.G., Azaretzky, M., Prolactinoma in children and adolescents. Horm Res. 72 (2009), 197–205.
68. 68 Halperin, I., Cámara, R., García, M., Ollero, D., Guía clínica de diagnóstico y tratamiento del prolactinoma y la hiperprolactinemia. Endocrinol Nutr. 60 (2013), 308–319.
69. 69 Prabhakar, V.K., Davis, J.R., Hyperprolactinemia. Best Pract Res Clin Obstet Gynaecol 22 (2008), 341–353.
70. 70 Majumdar, A., Mangal, N.S., Hyperprolactinemia. J Hum Reprod Sci 6 (2013), 168–175.
71. 71 Schlechte, J., El-Khoury, G., Kathol, M., Walkner, L., Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64 (1987), 1021–1026.
72. 72 Bobes, J., Garcia-Portilla, M.P., Rejas, J., Hernandez, G., Garcia-Garcia, M., Rico-Villademoros, F., et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. J Sex Marital Ther. 29 (2003), 125–147.
73. 73 Üçok, A., Incesu, C., Aker, T., Erkoc, S., Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry 22 (2007), 328–333.
74. 74 Montejo Al, Rico-Villademoros, F., Tafalla, M.A., Majadas, S., Grupo Español. 6-month prospective observational study on the effects of quetiapine on sexual functioning. J Clin Psychopharmacol. 5 (2005), 533–538.
75. 75 Knegtering, R., Castelein, S., Bous, H., van der Linde, J., Bruggeman, R., Kluiter, H., et al. A randomized open- label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol. 24 (2004), 56–61.
76. 76 Knegtering, H., Boks, M., Blijd, C., Castelein, S., van den Bosch, R.J., Wiersma, D., A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther. 32 (2006), 315–326.
77. 77 Montalvo, I., Ortega, L., López, X., Solé, M., Monseny, R., Franch, J., et al. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Int Clin Psychopharmacol. 28 (2013), 46–49.
78. 78 Serretti, A., Chiesa, A., A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 26 (2011), 130–140.
79. 79 Chiesa, A., Leucci, V., Serretti, A., Antipsychotics and sexual dysfunction: Epidemiology, mechanisms and management. Clin Neuropsychia 10 (2013), 31–36.
80. 80 Corona, G., Mannucci, E., Fisher, A.D., Lotti, F., Ricca, V., Balercia, G., et al. Effect of hyperprolactinemia in male patients consulting for sexual dysfunction. J Sex Med 4 (2007), 1485–1493.
81. 81 Maggi, M., Buvat, J., Corona, G., Guay, A., Torres, L.O., Hormonal causes of male sexual disfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). J Sex Med 10 (2013), 661–677.
82. 82 Kadioglu, P., Yalin, A.S., Tiryakioglu, O., Gazioglu, N., Oral, G., Sanli, O., et al. Sexual dysfunction in women with hyperprolactinemia: A pilot study report. J Urol 174 (2005), 1921–1925.
83. 83 Weiden, P.J., Miller, A.L., Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract. 7 (2001), 41–47.
84. 84 Olfson, M., Uttaro, T., Carson, W.H., Tafesse, E., Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry. 66 (2005), 331–338.
85. 85 Bebbington, P.E., Angermeyer, M., Azorin, J.M., Marwaha, S., Marteau, F., Toumi, M., Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl., 2009, 22–28.
86. 86 Rosenberg, K.P., Bleiberg, K.L., Koscis, J., Gross, C., A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: Impact on compliance. J Sex Marital Ther. 29 (2003), 289–296.
87. 87 Zemishlany, Z.L., Weizman, A., The impact of mental illness on sexual dysfunction. Adv Psychosom Med. 29 (2008), 89–106.
88. 88 Montejo AL, Montero Fernandez C, Pol Rodriguez J, Esquer Terrazas I, Romero del Río O, Fernandez Martin L.C., Dutil Muñoz V, et al. EPA-1652 Sexuality and emotional life in people with severe long-term mental. Disorders Eur Psychiatr. 2014;(29 suppl):1. Disponible en:http://dx.doi.org/10.1016/S0924-9338(14)78798-X.
89. 89 Cutler, A.J., Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 28:Suppl 1 (2003), 69–82.
90. 90 Haddad, P.M., Wieck, A., Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 64 (2004), 2291–2314.
91. 91 Baggaley, M., Sexual dysfunction in schizophrenia: Focus on recent evidence. Hum Psychopharmacol. 23 (2008), 201–209.
92. 92 Buvat, J., Shabsigh, R., Guay, A., Gooren, L., Torres, L.O., Meuleman, E., Hormones, metabolism, aging, and men's health. Montorsi, F., Basson, R., Adaikan, G., Becher, E., Clayton, A., Giuliano, F., et al. (eds.) Standard practice in sexual medicine., 2006, Blackwell Publishing, Oxford, 225–286.
93. 93 Drago, F., Pellegrini-Quarantotti, B., Scapagnini, U., Gessa, G.L., Short-term endogenus hyperprolactinemia and sexual behavior of me rats. Physiol Behav 26 (1981), 277–279.
94. 94 Yu-Lee, L.Y., Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res. 57 (2002), 435–455.
95. 95 Montes de Oca, P., Macotela, Y., Nava, G., López-Barrera, F., de la Escalera, G.M., Clapp, C., Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells. Lab Invest. 85 (2005), 633–642.
96. 96 Molinari, C., Grossini, E., Mary, D.A., Liberti, F., Ghigo, E., Ribichini, F., et al. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology. 148 (2007), 4080–4090.
97. 97 Kikuchi, T., Iwamoto, K., Sasada, K., Aleksic, B., Yoshida, K., Ozaki, N., Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 37 (2012), 26–32.
98. 98 Deanna, L.K., Wehring, J.H., Earl, K.A., Sullivan, M.K., Dickerson, B.F., Feldman, S., et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: Presentation of the ongoing DAAMSEL Clinical Trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated Prolactin). BMC Psychiatry, 13, 2013, 214.
99. 99 Windgassen, K.L., Wesselmann, U., Schulze Mönking, H., Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: Frequency and etiology. Neuropsychobiology. 33 (1996), 142–146.
100. 100 Kleinberg, D.L., Noel, G.L., Frantz, A.G., Galactorrhea: A study of 235 cases, incluiding 48 with pituitary tumors. N Engl J Med 296 (1977), 589–600.
101. 101 Boyd, A.E., Reivhlin, T., Turksoy, R.N., Galactorrhea-amenorrhea syndrome: Diagnosis and therapy. Ann Intern Med. 87 (1977), 165–175.
102. 102 Luciano, A.A., Clinical presentation of hyperprolactinemia. J Reprod Med. 44 (1999), 1085–1090.
103. 103 Pratheesh, P.J., Praharaj, S.K., Srivastava, A., Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination. Psychopharmacol Bull. 44 (2011), 70–73.
104. 104 Reynolds, C., Montone, K.T., Powell, C.M., Tomaszewski, J.E., Clevenger, C.V., Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138 (1997), 5555–5560.
105. 105 Partti, K., Heliövaara, M., Impivaara, O., Perälä, J., Saarni, S.I., Lönnqvist, J., et al. Skeletal status in psychotic disorders: A population-based study. Psychosom Med. 72 (2010), 933–940.
106. 106 Crews, M.P.K., Howes, O.D., Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol 27 (2012), 15–23.
107. 107 Renn, J.H., Yang, N.P., Chueh, C.M., Lin, C.Y., Lan, T.H., Chou, P., Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord., 10, 2009, 1.
108. 108 Abel, K.M., Heatlie, H.F., Howard, L.M., Webb, R.T., Sex and age-specific incidence of fractures in mental illness: A historical, population-based cohort study. J Clin Psychiatry. 69 (2008), 1398–1403.
109. 109 Carney, C.P., Jones, L., Woolson, R.F., Medical comorbidity in women and men with schizophrenia: A population-based controlled study. J Gen Intern Med. 21 (2006), 1133–1137.
110. 110 Cooper, J., Mancuso, S.G., Borland, R., Slade, T., Galletly, C., Castle, D., Tobacco smoking among people living with a psychotic illness: The second Australian Survey of Psychosis. Aust N Z J Psychiatry. 46 (2012), 851–863.
111. 111 Hedelin, M., Löf, M., Olsson, M., Lewander, T., Nilsson, B., Hultman, C.M., et al. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33,000 women from the general population. BMC Psychiatry., 26, 2010, 38.
112. 112 O'Keane, V., Meaney, A.M., Antipsychotic drugs: A new risk factor for osteoporosis in young women with schizophrenia?. J Clin Psychopharmacol. 25 (2005), 26–31.
113. 113 Takahashi, T., Uchida, H., John, M., Hirano, J., Watanabe, K., Mimura, M., et al. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort. Schizophr Res. 147 (2013), 383–386.
114. 114 Van der Leeuw, C., Habets, P., Domen, P., van Kroonenburgh, M., van Os, J., Marcelis, M., for G.R.O.U.P. Bone mineral density as a marker of cumulative endogenous estrogen exposure: Relationship to background genetic risk of psychotic disorder. Schizophr Res. 143 (2013), 25–31.
115. 115 Kinon, B.J., Liu-Seifert, H., Stauffer, V.L., Jacob, J., Bone loss associated with hyperprolactinemia in patients with schizophrenia. Clin Schizophr Relat Psychoses. 7 (2013), 115–123.
116. 116 Kishimoto, T., Watanabe, K., Shimada, N., Makita, K., Yagi, G., Kashima, H., Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 69 (2008), 385–391.
117. 117 Seriwatanachai, D., Krishnamra, N., van Leeuwen, J.P., Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J Cell Biochem. 107 (2009), 677–685.
118. 118 Mazziotti, G., Porcelli, T., Mormando, M., De Menis, E., Bianchi, A., Mejia, C., et al. Vertebral fractures in males with prolactinoma. Endocrine. 39 (2011), 288–293 Epub 2011 Apr 10.
119. 119 Wang, P.S., Walker, A.M., Tsuang, M.T., Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59 (2002), 1147–1154.
120. 120 Faupel-Badger, J.M., Duggan, M.A., Sherman, M.E., Garcia-Closas, M., Yang, X.R., Lissowska, J., et al. Prolactin receptor expression and breast cancer: Relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 5 (2014), 42–50.
121. 121 Clevenger, C.V., Furth, P.A., Hankinson, S.E., Schuler, L.A., The role of prolactin in mammary carcinoma. Endocr Rev 24 (2003), 1–27.
122. 122 Goffin, V., Bernichtein, S., Touraine, P., Kelly, P., Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 26 (2005), 400–422.
123. 123 Harvey, P.W., Everett, D.J., Springall, C.J., Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: Role in breast and prostate cancer. Hum Exp Toxicol. 25 (2006), 395–404.
124. 124 Hankinson, S.E., Willett, W.C., Michaud, D.S., Manson, J., Colditz, G., Longcope C., et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 91 (1999), 629–634.
125. 125 Manjer, J., Johansson, R., Berglund, G., Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control. 14 (2003), 599–607.
126. 126 Tworoger, S.S., Sluss, P., Hankinson, S.E., Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 66 (2006), 2476–2482.
127. 127 Tworoger, S.S., Eliassen, A.H., Sluss, P., Hankinson, S.E., A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 25 (2007), 1482–1488.
128. 128 Tworoger, S.S., Eliassen, A.H., Zhang, X., Qian, J., Sluss, P.M., Rosner, B.A., et al. 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 73 (2013), 4810–4819.
129. 129 Tworoger, S.S., Hankinson, S.E., Prolactin and breast cancer etiology: An epidemiologic perspective. J Mammary Gland Biol Neoplasia 13 (2008), 41–53.
130. 130 Mor, G., Visintin, I., Lai, Y., Zhao, H., Schwartz, P., Rutherford, T., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 102 (2005), 7677–7682.
131. 131 Yurkovetsky, Z., Ta'asan, S., Skates, S., Rand, A., Lomakin, A., Linkov, F., et al. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol 107 (2007), 58–65.
132. 132 Levina, V., Nolen, B., Su, Y., Godwin, A., Fishman, D., Liu, J., et al. Biological significance of prolactin in gynecological cancers. Cancer Res. 69 (2009), 5226–5233.
133. 133 Stattin, P., Rinaldi, S., Stenman, U.H., Riboli, E., Hallmans, G., Bergh, A., et al. Plasma prolactin and prostate cancer risk: A prospective study. Int J Cancer 92 (2001), 463–465.
134. 134 Berinder, K., Akre, O., Granath, F., Hulting, A.L., Cancer risk in hyperprolactinemia patients: A population-based cohort study. Eur J Endocrinol. 165 (2011), 209–215.
135. 135 Georgiopoulos, G.A., Stamatelopoulos, K.S., Lambrinoudaki, I., Likka, M., Kyrkou, K., Rizos, M., et al. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54 (2009), 98–105.
136. 136 Shibli-Rahhal, A., Schlechte, J., The effects of hyperprolactinemia on bone and fat. Pituitary. 12 (2009), 96–104.
137. 137 Erem, C., Kocak, M., Nuhoglu, I., Yilmaz, M., Ucuncu, O., Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf). 73 (2010), 502–527.
138. 138 Friedrich, N., Schneider, H.J., Spielhagen, C., Markus, M.R., Haring, R., Grabe, H.J., et al. The association of serum prolactin concentration with inflammatory biomarkers–cross-sectional findings from the population-based study of health in Pomerania. Clin Endocrinol (Oxf) 75 (2011), 561–566.
139. 139 Yavuz, D., Deyneli, O., Akpinar, I., Yildiz, E., Gözü, H., Sezgin, O., et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 149 (2003), 187–193.
140. 140 Malaguarnera, L., Pilastro, M.R., Quan, S., Ghattas, M.H., Yang, L., Mezentsev, A.V., et al. Significance of heme oxygenase in prolactin-mediated cell proliferation and angiogenesis in human endothelial cells. Int J Mol Med 10 (2002), 433–440.
141. 141 Goldhar, A.S., Vonderhaar, B.K., Trott, J.F., Hovey, R.C., Prolactin induced expression of vascular endothelial growth factor via Egr-1. Mol Cell Endocrinol 232 (2005), 9–19.
142. 142 Wallaschofski, H., Donné, M., Eigenthaler, M., Hentschel, B., Faber, R., Stepan, H., et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab. 86 (2001), 5912–5919.
143. 143 Arslan, M., Topaloglu, O., Sahin, M., Tutal, E., Gungunes, A., Cakir, E., et al. Preclinical atherosclerosis in patients with prolactinoma. Endocr Pract 20 (2014), 447–451.
144. 144 Reuwer, A.Q., Twickler, M.T., Hutten, B.A., Molema, F., Wareham, N., Dallinga-Thie, G., et al. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet 2 (2009), 389–395.
145. 145 Reuwer, A.Q., van Eijk, M., Houttuijn-Bloemendaal, F.M., van der Loos Ch, Claessen, N., Teeling, P., et al. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: A role for prolactin in atherogenesis?. J Endocrinol. 208 (2011), 107–117.
146. 146 Ben-Jonathan, N., Hugo, E.R., Brandebourg, T.D., LaPensee, C.R., Focus on prolactin as a metabolic hormone. Trends in endocrinology andmetabolism. TEM 17 (2006), 110–116.
147. 147 Brandebourg, T., Hugo, E., Ben-Jonathan N:, Adipocyte prolactin: Regulation of release and putative functions. Diabetes Obes Metab 9 (2007), 464–476.
148. 148 Ling, C., Svensson, L., Odén, B., Weijdegard, B., Edén, B., Edén, S., et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 88 (2003), 1804–1808.
149. 149 Mingrone, G., Manco, M., Iaconelli, A., Gniuli, D., Bracaglia, R., Leccesi, L., et al. Prolactin and insulin ultradian secretion and adipose tissue lipoprotein lipase expression in severely obese women after bariatric surgery. Obesity (Silver Spring) 16 (2008), 1831–1837.
150. 150 Freemark, M., Avril, I., Fleenor, D., Driscoll, P., Petro, A., Opara, E., et al. Targeted deletion of the PRL receptor: Effects on islet development, insulin production, and glucose tolerance. Endocrinology 143 (2002), 1378–1385.
151. 151 Brelje, T.C., Stout, L.E., Bhagroo, N.V., Sorenson, R.L., Distinctive roles for prolactinand growth hormone in the activation of signal transducer and activatorof transcription 5 in pancreatic islets of langerhans. Endocrinology 145 (2004), 4162–4175.
152. 152 Serri, O., Li, L., Mamputu, J.C., Beauchamp, M.C., Maingrette, F., Renier, G., The influences of hyperprolactinemia and obesity on cardiovascular risk markers: Effects of cabergoline therapy. Clin Endocrinol (Oxf). 64 (2006), 366–370.
153. 153 Ernst, B., Thurnheer, M., Schultes B:, Basal serum prolactin levels in obesity– unrelated to parameters of the metabolic syndrome and unchanged after massive weight loss. Obes Surg 19 (2009), 1159–1162.
154. 154 Balbach, L., Wallaschofski, H., Völzke, H., Nauck, M., Dörr, M., Haring, R., Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?. Endocr Dis 13 (2013), 12–19.
155. 155 Creemers, L.B., Zelissen, P.M., van ‘t Verlaat, J.W., Koppeschaar, H.P., Prolactinoma and body weight: A retrospective study. Acta Endocrinol 125 (1991), 392–396.
156. 156 Delgrange, E., Donckier, J., Maiter, D., Hyperprolactinaemia as a reversible cause of weight gain in male patients?. Clin Endocrinol (Oxf), 50, 1999, 271.
157. 157 Doknic, M., Pekic, S., Zarkovic, M., Medic-Stojanoska, M., Dieguez, C., Casanueva, F., et al. Dopaminergic tone and obesity: An insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 147 (2002), 77–84.
158. 158 Nilsson, L., Binart, N., Bohlooly, Y.M., Bramnert, M., Egeciouglu, E., Kindblom, J., et al. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331 (2005), 1120–1126.
159. 159 Vera-Lastra, O., Jara, L.J., Espinoza, L.R., Prolactin and autoimmunity. Autoimmun Rev. 1 (2002), 360–364.
160. 160 Atasoy, M., Karatay, S., Yildirim, K., Kadi, M., Erdem, T., Senel, K., The relationship between serum prolactin levels and disease activity in patients with Behçet's disease. Cell Biochem Funct 24 (2006), 353–356.
161. 161 Leanos-Miranda, A., Cardenas-Mondragon, G., Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology 45 (2006), 97–101.
162. 162 Poyraz, B.C., Aksoy, C., Balcioğ lu, I., Increased incidence of autoimmune thyroiditis in patients with antipsychotic- induced hyperprolactinemia. Eur Neuropsychopharmacol 18 (2008), 667–672.
163. 163 Orbach, H., Shoenfeld, Y., Hyperprolactinemia and autoinmune diseases. Autoimmun Rev 6 (2007), 537–542.
164. 164 Shelly, S., Boach, M., Orbach, H., Prolantin and autoimmunity. Autoimmun Rev. 11 (2012), A465–A470.
165. 165 Henry, J.F., Sherwin, B.B., Hormones and cognitive functioning during late pregnancy and pospartum: A longitudinal study. Behav Neurosci 126 (2012), 73–85.
166. 166 Phillips, S.M., Sherwin, B.B., Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 17 (1992), 485–495.
167. 167 Grigorova, M., Sherwin, B.B., Effects of treatment with luprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology 31 (2006), 935–947.
168. 168 Craig, M.C., Fletcher, P.C., Daly, E.M., Rymer, J., Cutter, W.J., Brammer, M., et al. Gonadotropin hormone releasing hormone agonists alter prefrontal function during verbal encoding in young women. Psychoneuroendocrinology. 32 (2007), 1116–1127.
169. 169 Craig, M.C., Fletcher, P.C., Daly, E.M., Picchioni, M.M., Brammer, M., Giampietro, V., et al. A study of visuospatial working memory pre- and post-gonadotropin hormone releasing hormone agonists (GnRHa) in young women. Horm Behav. 54 (2008), 47–59.
170. 170 Moffat, S.D., Zonderman, A.B., Metter, E.J., Blackman, M.R., Harman, S.M., Resnick, S.M., Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 87 (2002), 5001–5007.
171. 171 Beer, T.M., Bland, L.B., Bussiere, J.R., Neiss, M.B., Wersinger, E.M., Garzotto, M., et al. Testosterone loss and estradiol administration modify memory in men. J Urol. 175 (2006), 130–135.
172. 172 Pinsky, M., Hellstrom, W., Hypogonadism, ADAM, and hormone replacement. Ther Adv Urol 2 (2010), 99–104.
173. 173 Moffat, S.D., Zonderman, A.B., Metter, E.J., Kawas, C., Blackman, M.R., Harman, S.M., et al. Free testosterone and risk for Alzheimer disease in older men. Neurology 62 (2004), 188–193.
174. 174 Fava, M., Fava, G.A., Kellner, R., Buckman, M.T., Lisansky, J., Serafini, E., et al. Psychosomatic aspects of hyperprolactinemia. Psychother Psychosom 40:1–4 (1983), 257–262.
175. 175 Reavley, A., Fisher, A.D., Owen, D., Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol. 47 (1997), 343–347.
176. 176 Oliveira, M., Pizarro, C., Golbert, L., Micheletto, C., Hiperprolactinemia e distúrbios psiquiátricos. Arq Neuropsiquiatr 58 (2000), 671–676.
177. 177 Sobrinho, L.G., Emotional aspects of hyperprolactinemia. Psychother Psychosom. 67 (1998), 133–139.
178. 178 Peveler, R.C., Branford, D., Citrome, L., Fitzgerald, P., Harvey, P.W., Holt, R.I., et al. Antipsychotics and hyperprolactinaemia: Clinical recommendations. J PsychopharmacolV 22(2 Suppl), 2008, 98–103.